Side-by-side evidence map
| Question | Retatrutide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1, GIP, and glucagon agonism | GLP-1 agonism |
| Regulatory status | Investigational | FDA-approved for specific indications |
| Core evidence | Phase 2 peer-reviewed; Phase 3 program active | Large phase 3 programs and approved labeling |
| Direct comparison | No head-to-head trial | No head-to-head trial |
How to read the numbers
A larger percentage reported in one trial does not prove superiority over a result from another trial. A valid treatment comparison requires a head-to-head design or a carefully specified indirect analysis.
What this evidence review covers
Compare mechanism, status, and separate trial evidence without claiming head-to-head superiority.
- One-row status and receptor comparison
- Retatrutide phase 2 obesity study
- Semaglutide STEP 1 study
- Why percentages cannot be ranked across different trials
- Approved-product versus vendor-material boundary
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
mechanism
Retatrutide activates GIP, GLP-1, and glucagon receptors; semaglutide is a GLP-1 receptor agonist.
cross-trial limitation
The cited studies differ in population, design, duration, and intervention; comparison is descriptive, not head-to-head.
| Evidence class | What the source supports |
|---|---|
| mechanism | Retatrutide activates GIP, GLP-1, and glucagon receptors; semaglutide is a GLP-1 receptor agonist. |
| cross-trial limitation | The cited studies differ in population, design, duration, and intervention; comparison is descriptive, not head-to-head. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
STEP 1 semaglutide obesity trial
Evidence class: primary randomized phase 3. What it supports: n=1,961; approved-product trial context; 68-week weight and adverse-event results in a defined population.
What it does not establish: A head-to-head comparison with retatrutide or equivalence of unapproved semaglutide material.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
Questions this page answers
Which caused more weight loss?
Do not declare a winner from separate trials. Present each estimate with trial context and explicitly state there was no direct randomized comparison in the packet.
Are both approved?
Approved semaglutide products exist for defined uses; Retatrutide remains investigational in the inspected FDA source.
What remains unresolved
- No direct head-to-head trial.
- Current semaglutide label should be rechecked at publication.
- No treatment recommendation or switching guidance.